Patents by Inventor Hyung-Kyu Lim
Hyung-Kyu Lim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170360939Abstract: The present invention relates to an albumin-free liquid formulation comprising a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, as well as a method for preparing the liquid formulation. The liquid formulation comprises a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection.Type: ApplicationFiled: June 29, 2017Publication date: December 21, 2017Inventors: Hyun Uk Kim, Hyung Kyu Lim, Myung Hyun Jang, Sang Yun Kim, Sung Min Bae, Se Chang Kwon
-
Patent number: 9833516Abstract: The present invention relates to a liquid formulation of a combination of long-acting insulin and insulinotropic peptide, comprising insulin which is a physiologically active peptide, insulinotropic peptide, and albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent; and a method for preparing the liquid formulation. The liquid formulation of the present invention does not contain a human serum albumin and potentially toxic factors to the body, and thus it has excellent storage stability for insulin conjugate and insulinotropic peptide conjugate at high concentration, without a risk of viral contamination.Type: GrantFiled: July 25, 2013Date of Patent: December 5, 2017Assignee: HANMI PHARM. CO., LTDInventors: Hyung Kyu Lim, Hyun Uk Kim, Mi Kyoung Lee, Jong Soo Lee, Sung Min Bae, Se Chang Kwon
-
Patent number: 9801950Abstract: The present invention relates to a liquid formulation of long-acting insulinotropic peptide conjugate, comprising a pharmaceutically effective amount of long-acting insulinotropic peptide conjugate consisting of a physiologically active peptide, insulinotropic peptide, and an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For the purpose of preventing microbial contamination, a preservative may be added. The liquid formulation of the present invention is free of human serum albumin and other potentially hazardous factors to body, having no risk of viral contamination, and thus can provide excellent storage stability for insulinotropic peptide conjugates at high concentration.Type: GrantFiled: July 25, 2013Date of Patent: October 31, 2017Assignee: HANMI PHARM. CO., LTD.Inventors: Hyun Uk Kim, Hyung Kyu Lim, Sung Hee Hong, Dae Jin Kim, Sung Min Bae, Se Chang Kwon
-
Patent number: 9724420Abstract: Disclosed are an albumin-free liquid formulation including a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, and a method for preparing the liquid formulation. The liquid formulation contains a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection. The oxyntomodulin conjugate contains oxyntomodulin linked to an immunoglobulin Fc region, and thus has a large molecular weight, prolonged physiological activity, and excellent storage stability, compared to native oxyntomodulin.Type: GrantFiled: November 6, 2013Date of Patent: August 8, 2017Assignee: Hanmi Pharm. Co., Ltd.Inventors: Hyun Uk Kim, Hyung Kyu Lim, Myung Hyun Jang, Sang Yun Kim, Sung Min Bae, Se Chang Kwon
-
Publication number: 20170128589Abstract: The present invention relates to a method for improving the solubility of a physiologically active protein or peptide compared to that of a physiologically active protein or peptide which is not conjugated to an immunoglobulin Fc fragment, in which the method comprises conjugating the physiologically active protein or peptide to an immunoglobulin Fc fragment; and a composition for improving the solubility of a physiologically active protein or peptide, comprising an immunoglobulin Fc fragment, in which the composition improves the solubility compared to a composition without an immunoglobulin Fc fragment.Type: ApplicationFiled: March 31, 2015Publication date: May 11, 2017Applicant: HANMI PHARM. CO., LTD.Inventors: Hyung Kyu LIM, Jong Soo LEE, Dae Jin KIM, Sung Min BAE, Sung Youb JUNG, Se Chang KWON
-
Publication number: 20170100488Abstract: The present invention relates to a method for increasing serum half-life of a protein or peptide and decreasing immunogenicity thereof by site-specifically binding a carrier to a protein or peptide, and to the use thereof. The conjugate of the physiologically active protein or peptide of the present invention can significantly decrease immunogenicity in the human body and thus reduce antibody production rate against the protein or peptide. Therefore, the present conjugate has advantages in that a phenomenon of reduced clinical effects of the physiologically active protein or peptide is low, and it can be effectively used in the development of long-acting formulations having a high safety against the immune response.Type: ApplicationFiled: June 5, 2015Publication date: April 13, 2017Applicant: HANMI PHARM. CO., LTD.Inventors: Sung Hee PARK, Seung Su KIM, Hyung Kyu LIM, Jae Hyuk CHOI, In Young CHOI, Se Chang KWON
-
Publication number: 20170066811Abstract: The present invention relates to a novel insulin analog, and more specifically, to an insulin analog with an improved in vitro effect compared with native insulin, a nucleic acid encoding the same, an expression vector including the nucleic acid, a transformant introduced with the expression vector, a method of producing the insulin analog from the transformant, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition.Type: ApplicationFiled: August 29, 2016Publication date: March 9, 2017Inventors: Jin Young KIM, Euh Lim OH, Jong Soo LEE, Hyung Kyu LIM, In Young CHOI, Se Chang KWON
-
Publication number: 20160213789Abstract: The present invention relates to a sustained type human growth hormone conjugate preparation comprising: a sustained type human growth hormone (hGH) conjugate resulting from conjugation between the immunoglobulin Fc region and a human growth hormone (hGH) constituting a bioactive peptide; a buffer solution; a nonionic surfactant; and a sugar alcohol. More specifically, the present invention relates to a sustained type human growth hormone conjugate freeze dried preparation and liquid preparation, to a production method for the freeze dried preparation, to a method of reconstituting the freeze dried preparation, and to a kit comprising the freeze dried preparation and a reconstituting solution.Type: ApplicationFiled: September 26, 2014Publication date: July 28, 2016Applicant: HANMI PHARM. CO., LTD.Inventors: Hwa Peoung RIM, Hyun Uk KIM, Ho Taek IM, Sang Yun KIM, Hyung Kyu LIM, Sung Min BAE, Se Chang KWON
-
Patent number: 9379377Abstract: Disclosed is a cathode for a lithium secondary battery and a lithium secondary battery comprising the same. The cathode may include a current collector, a first composite layer formed from a mixture of olivine-type lithium iron phosphate cathode active material powder and a binder on the current collector, and a second composite layer formed from a mixture of olivine-type lithium iron phosphate cathode active material powder and a binder on the first composite layer. A specific surface area of the olivine-type lithium iron phosphate cathode active material powder in the second composite layer may be at least 1.2 times larger than that of the olivine-type lithium iron phosphate cathode active material powder in the first composite layer. The cathode for a lithium secondary battery has excellent safety, high energy density, and high output performance.Type: GrantFiled: March 28, 2013Date of Patent: June 28, 2016Assignee: LG Chem, Ltd.Inventors: Jong-Hee Kim, Hyung-Kyu Lim, In-Jung Kim, In-Seok Yang, Seok-Jung Park
-
Publication number: 20160158378Abstract: Provided is a long-acting pharmaceutical composition containing a conjugate comprising a physiologically active polypeptide linked to an immunoglobulin Fc fragment, wherein the composition contains a monomeric conjugate comprising one molecule of the physiologically active polypeptide linked to a single immunoglobulin Fc fragment, and optionally contains a multimeric conjugate comprising two or more molecules of the same physiologically active polypeptide linked to a single immunoglobulin Fc fragment, provided that the molar ratio of the monomeric conjugate to the multimeric conjugate in the composition is at least 19; a physiologically active polypeptide monomer-immunoglobulin Fc fragment conjugate that comprises a physiologically active polypeptide monomer linked via a non-peptidyl linker to an immunoglobulin Fc fragment, wherein the physiologically active polypeptide is linked via the non-peptidyl linker to the immunoglobulin Fc fragment in a monomeric form.Type: ApplicationFiled: July 14, 2014Publication date: June 9, 2016Applicant: HANMI PHARM. CO., LTD.Inventors: Sung Hee PARK, Min Young KIM, Hyung Kyu LIM, Sung Min BAE, Sung Youb JUNG, Se Chang KWON
-
Patent number: 9178209Abstract: Disclosed is a cathode for a lithium secondary battery and a lithium secondary battery comprising the same. The cathode for a lithium secondary battery may include a current collector, a first composite layer formed from a mixture of olivine-type lithium iron phosphate cathode active material powder and a binder on the current collector, and a second composite layer formed from a mixture of olivine-type lithium iron phosphate cathode active material powder and a binder on the first composite layer. A specific surface area of the olivine-type lithium iron phosphate cathode active material powder in the second composite layer may be 0.8 times or less that of the olivine-type lithium iron phosphate cathode active material powder in the first composite layer. The cathode for a lithium secondary battery has excellent stability, high energy density, and improved cycle life characteristics.Type: GrantFiled: March 28, 2013Date of Patent: November 3, 2015Assignee: LG Chem, Ltd.Inventors: Jong-Hee Kim, Hyung-Kyu Lim, In-Jung Kim, In-Seok Yang, Seok-Jung Park
-
Publication number: 20150290324Abstract: Disclosed are an albumin-free liquid formulation including a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, and a method for preparing the liquid formulation. The liquid formulation contains a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection. The oxyntomodulin conjugate contains oxyntomodulin linked to an immunoglobulin Fc region, and thus has a large molecular weight, prolonged physiological activity, and excellent storage stability, compared to native oxyntomodulin.Type: ApplicationFiled: November 6, 2013Publication date: October 15, 2015Applicant: HANMI PHARM. CO., LTD.Inventors: Hyun Uk Kim, Hyung Kyu Lim, Myung Hyun Jang, Sang Yun Kim, Sung Min Bae, Se Chang Kwon
-
Publication number: 20150238629Abstract: The present invention relates to a liquid formulation of long-acting insulinotropic peptide conjugate, comprising a pharmaceutically effective amount of long-acting insulinotropic peptide conjugate consisting of a physiologically active peptide, insulinotropic peptide, and an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For the purpose of preventing microbial contamination, a preservative may be added. The liquid formulation of the present invention is free of human serum albumin and other potentially hazardous factors to body, having no risk of viral contamination, and thus can provide excellent storage stability for insulinotropic peptide conjugates at high concentration.Type: ApplicationFiled: July 25, 2013Publication date: August 27, 2015Applicant: HANMI PHARM. CO., LTD.Inventors: Hyun Uk Kim, Hyung Kyu Lim, Sung Hee Hong, Dae Jin Kim, Sung Min Bae, Se Chang Kwon
-
Publication number: 20150196643Abstract: The present invention relates to a liquid formulation of long-acting insulin conjugate, comprising a pharmaceutically effective amount of a long-acting insulin conjugate, wherein a physiologically active peptide, which is an insulin, is linked to an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For preventing microbial contamination in multiple uses, a preservative can be added to the formulation. The liquid formulation of the present invention does not comprise a human serum albumin and potentially hazardous factors to body, and thus it has excellent storage stability for insulin conjugate without a risk of viral infection.Type: ApplicationFiled: July 25, 2013Publication date: July 16, 2015Applicant: HANMI PHARM. CO., LTD.Inventors: Hyung Kyu Lim, Hyun Uk Kim, Sung Hee Hong, Min Young Kim, Sung Min Bae, Se Chang Kwon
-
Publication number: 20150190528Abstract: The present invention relates to a liquid formulation of a combination of long-acting insulin and insulinotropic peptide, comprising insulin which is a physiologically active peptide, insulinotropic peptide, and albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent; and a method for preparing the liquid formulation. The liquid formulation of the present invention does not contain a human serum albumin and potentially toxic factors to the body, and thus it has excellent storage stability for insulin conjugate and insulinotropic peptide conjugate at high concentration, without a risk of viral contamination.Type: ApplicationFiled: July 25, 2013Publication date: July 9, 2015Applicant: HANMI PHARM. CO., LTD.Inventors: Hyung Kyu Lim, Hyun Uk Kim, Mi Kyoung Lee, Jong Soo Lee, Sung Min Bae, Se Chang Kwon
-
Publication number: 20150118255Abstract: The present invention relates to a liquid formulation of highly concentrated long-acting human growth hormone conjugate, comprising a pharmaceutically effective amount of the long-acting human growth hormone conjugate in which human growth hormone (hGH) is linked to an immunoglobulin Fc region, and an albumin-free stabilizer, said stabilizer comprising a buffer, a non-ionic surfactant, a sugar alcohol, and sodium chloride as an isotonic agent, and a method for preparing the same.Type: ApplicationFiled: March 29, 2013Publication date: April 30, 2015Applicant: HANMI SCIENCE CO., LTDInventors: Hyung Kyu Lim, Hyun Uk Kim, Sung Hee Hong, Sung Min Bae, Se Chang Kwon
-
Patent number: 8738183Abstract: An apparatus which provides various functions for physical and/or mental relaxation, as well as for health care of a user, and a method of implementing the apparatus, include downloading personal data of the user from a user terminal to a personally customized bed and controlling one or more functions of the personally customized bed based on the personal data.Type: GrantFiled: January 7, 2009Date of Patent: May 27, 2014Assignee: Samsung Electronics Co., Ltd.Inventors: Woo-young Jang, Hyung-kyu Lim, Dong-wook Kim
-
Patent number: 8728650Abstract: An apparatus for enhancing impregnation of the electrolyte in a secondary battery includes a tray in which at least one battery cell is received, and an oscillation and rotation unit capable of oscillating and rotating the tray simultaneously.Type: GrantFiled: November 6, 2012Date of Patent: May 20, 2014Assignee: LG Chem, Ltd.Inventors: In-Jung Kim, Jong-Hee Kim, Hyung-Kyu Lim, In-Seok Yang, Seok-Jung Park
-
Publication number: 20090193578Abstract: An apparatus which provides various functions for physical and/or mental relaxation, as well as for health care of a user, and a method of implementing the apparatus, include downloading personal data of the user from a user terminal to a personally customized bed and controlling one or more functions of the personally customized bed based on the personal data.Type: ApplicationFiled: January 7, 2009Publication date: August 6, 2009Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: Woo-young Jang, Hyung-kyu Lim, Dong-wook Kim
-
Patent number: 6141282Abstract: A circuit for designating an operating mode of a packaged semiconductor memory device includes a first fuse mounted on the device. A plurality of pads mounted on the device are accessible to a user after the device is packaged. A mode selection circuit generates a first signal when the first fuse is open and a second signal when the first fuse is closed. A first-fuse opening circuit is operably connected to the pads and opens the first fuse responsive to a predetermined first-fuse cutting signal on the pads. In another aspect of the invention, a second fuse may be opened responsive to a predetermined second-fuse cutting signal on the pads. When the second fuse opens, the first-fuse opening circuit is disabled to prevent accidental opening of the first fuse when the desired operating mode requires the first fuse to be maintained intact.Type: GrantFiled: January 20, 1999Date of Patent: October 31, 2000Assignee: Samsung Electronics, Co., Ltd.Inventors: Choong-Sun Chin, Hyung-Kyu Lim